Literature DB >> 23184498

Growth of HepG2 cells was suppressed through modulation of STAT6/IL-4 and IL-10 in RAW 264.7 cells treated by phytoglycoprotein (38 kDa).

Jin Lee1, Kye-Taek Lim.   

Abstract

Macrophage type 2 (M2) is closely associated with tumor progression and metastasis. Thus, in this study, the antitumor effect of Styrax japonica Siebold et al. Zuccarini (SJSZ) glycoprotein on HepG2 cell proliferation through modulating M2 was investigated by measuring [³H]-thymidine incorporation and proliferating cell nuclear antigen (PCNA), nitric oxide (NO), reactive oxygen species (ROS), mitogen-activated protein kinases, signal transducer and activator of transcription (STAT) 6, cytokines [interleukin (IL)-4, IL-10, IL-12, and interferon (IFN)-γ], and CD163-positive cells using biochemical analysis, radioactivity, Western blot, ELISA, quantitative real-time polymerase chain reaction, and flow cytometry in coculture system. RAW 264.7 cells were found to be cytotoxic to HepG2 cells but [³H]-thymidine incorporation and expression of PCNA was suppressed in the presence of the SJSZ glycoprotein (20 μg/ml). The SJSZ glycoprotein normalized production of NO and ROS and expression of inducible nitric oxide synthase, IFN-γ, and IL-12 but suppressed expression of pSTAT6, IL-4, IL-10, and CD163-positive cells. Thus, the results of this study suggest that the SJSZ glycoprotein suppresses proliferation of HepG2 cells by modulating M2.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23184498     DOI: 10.1007/s10753-012-9576-9

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  33 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  cAMP-mediated inhibition of DNA replication and S phase progression: involvement of Rb, p21Cip1, and PCNA.

Authors:  Soheil Naderi; Jean Y J Wang; Tung-Ti Chen; Kristine B Gutzkow; Heidi K Blomhoff
Journal:  Mol Biol Cell       Date:  2005-01-12       Impact factor: 4.138

3.  p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation.

Authors:  Dennis Sohn; Frank Essmann; Klaus Schulze-Osthoff; Reiner U Jänicke
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

Review 4.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

5.  Identification of a Stat-6-responsive element in the promoter of the human interleukin-4 gene.

Authors:  R E Curiel; R Lahesmaa; J Subleski; M Cippitelli; R A Kirken; H A Young; P Ghosh
Journal:  Eur J Immunol       Date:  1997-08       Impact factor: 5.532

Review 6.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).

Authors:  Roniel Cabrera; Miguel Ararat; Mengde Cao; Yiling Xu; Clive Wasserfall; Mark A Atkinson; Chen Liu; David R Nelson
Journal:  Dig Dis Sci       Date:  2010-02       Impact factor: 3.199

8.  Growth factor requirements for survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors.

Authors:  A G Leary; H Q Zeng; S C Clark; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 9.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

10.  Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma.

Authors:  I O Ng; E C Lai; S T Fan; M Ng; A S Chan; M K So
Journal:  Cancer       Date:  1994-05-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.